WO2005061001A1 - 癌の抑制方法 - Google Patents
癌の抑制方法 Download PDFInfo
- Publication number
- WO2005061001A1 WO2005061001A1 PCT/JP2004/019800 JP2004019800W WO2005061001A1 WO 2005061001 A1 WO2005061001 A1 WO 2005061001A1 JP 2004019800 W JP2004019800 W JP 2004019800W WO 2005061001 A1 WO2005061001 A1 WO 2005061001A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- synoviolin
- protein
- expression
- function
- inhibiting
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 206010028980 Neoplasm Diseases 0.000 title claims description 44
- 201000011510 cancer Diseases 0.000 title claims description 42
- 230000000694 effects Effects 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 13
- 230000003213 activating effect Effects 0.000 claims abstract description 10
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 160
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 148
- 101001048065 Drosophila melanogaster E3 ubiquitin-protein ligase HRD1 Proteins 0.000 claims description 136
- 230000014509 gene expression Effects 0.000 claims description 76
- 230000002401 inhibitory effect Effects 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 239000004055 small Interfering RNA Substances 0.000 claims description 33
- 108020004459 Small interfering RNA Proteins 0.000 claims description 29
- 230000004913 activation Effects 0.000 claims description 22
- 230000005764 inhibitory process Effects 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 230000034512 ubiquitination Effects 0.000 claims description 19
- 238000010798 ubiquitination Methods 0.000 claims description 18
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 7
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000000865 phosphorylative effect Effects 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 8
- 108700025716 Tumor Suppressor Genes Proteins 0.000 abstract description 4
- 102000044209 Tumor Suppressor Genes Human genes 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 57
- 230000006870 function Effects 0.000 description 52
- 210000004940 nucleus Anatomy 0.000 description 25
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000026731 phosphorylation Effects 0.000 description 16
- 238000006366 phosphorylation reaction Methods 0.000 description 16
- 102000000872 ATM Human genes 0.000 description 15
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 238000001262 western blot Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 9
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 229960001948 caffeine Drugs 0.000 description 9
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000009368 gene silencing by RNA Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- 210000004748 cultured cell Anatomy 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 102000009097 Phosphorylases Human genes 0.000 description 5
- 108010073135 Phosphorylases Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000002437 synoviocyte Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108010039627 Aprotinin Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 101100507451 Drosophila melanogaster sip3 gene Proteins 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 3
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000003633 gene expression assay Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- -1 wafl / cipl Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010091356 Tumor Protein p73 Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102100030018 Tumor protein p73 Human genes 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000010379 pull-down assay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 102000054184 GADD45 Human genes 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 230000010305 self ubiquitination Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Definitions
- the present invention relates to a method for activating a p53 tumor suppressor gene or a p53 protein to localize the p53 protein to the nucleus.
- the present invention also relates to a pharmaceutical composition comprising a substance that promotes activation of a p53 tumor suppressor gene or a p53 protein.
- Synopiolin is a novel protein discovered as a membrane protein overexpressed in synovial cells from rheumatic patients (WO02 / 052007). Studies using genetically modified animals have revealed that Synoviolin is an essential molecule for the development of rheumatoid arthritis.
- Synoviolin has a RING finger motif. This motif is frequently found in an enzyme called E3 ubiquitin ligase, which plays an important role in protein ubiquitination, but in fact, siobiolin exerts one of the features of E3 ubiquitin ligase on its self-ubiquitination activity. Has been proven (WO02 / 052007).
- the p53 gene is located on chromosome 17 pl3, and is a very important tumor suppressor gene in the development and proliferation of cancer cells.
- the p53 protein recognizes a specific base sequence [5 '-(A / T) GPyPyPy-3') on DNA and promotes transcriptional activation of specific genes such as wafl / cipl, GADD45, and BAX. Also, (i) repression of the transcription of many other genes; (ii) viral oncogenes such as SV40 large T antigen, adenovirus EIB protein, nopirovirus E6, or cellular oncogenes such as mdm2. Physiological functions such as binding to DNA containing mismatches and (iii) specific binding to DNA containing mismatches are known.
- the present invention relates to a method for promoting the activation of a p53 tumor suppressor gene or p53 protein, and a method for promoting the activation of a p53 tumor suppressor gene or p53 protein. It is intended to provide a pharmaceutical composition to promote.
- the present inventor has conducted intensive studies in order to solve the above problems.
- synoviolin homo-knockout animal was analyzed in detail, a greater number of cells undergoing apoptosis were observed than in the wild type, and p53 protein, which is deeply involved in inducing apoptosis, was expressed in the nucleus. And was found to be strongly expressed. Then, they found that by inhibiting the function of synoviolin, the p53 tumor suppressor gene or 53 tumor suppressor protein was activated to inhibit the growth of cancer cells, thereby completing the present invention.
- the present invention is as follows.
- a pharmaceutical composition comprising a substance that activates a p53 tumor suppressor gene or promotes the activity of a p53 protein.
- composition according to (1) wherein the substance that promotes activation of the p53 tumor suppressor gene or p53 protein is a synoviolin expression and / or function inhibitor.
- composition according to (2) wherein the substance inhibiting synoviolin expression and / or function is siRNA or shRNA against a gene encoding synoviolin.
- composition according to any one of (1) to (5) for treating cancer.
- a method for localizing p53 protein to the nucleus which comprises inhibiting the expression and / or function of synoviolin.
- a method for inhibiting cancer comprising inhibiting the expression and / or function of synoviolin to localize the p53 protein to the nucleus.
- a method for phosphorylating a part of amino acid residues of p53 protein which comprises inhibiting the expression and / or function of Synoviolin.
- a method for activating a phosphorylase comprising inhibiting the expression and / or function of synoviolin.
- a method for suppressing cancer which comprises inducing p53 protein to induce expression of p21 protein by inhibiting the expression and / or function of synoviolin.
- a method for inhibiting ubiquitination of p53 protein which comprises inhibiting the expression and / or function of Synoviolin.
- Synoviolin's inhibition of function causes synoviolin to bind to p53 protein.
- FIG. 1 is a photograph showing the results of immunohistochemical staining of synoviolin homonockato mouse embryonic fibroblasts (MEFs).
- FIG. 2 is a photograph showing the results of immunohistochemical staining with an anti-p53 antibody in embryos of syno.
- FIG. 3 is a photograph showing the result of western blotting for p53.
- FIG. 4 is a photograph showing the results of identifying the phosphorylation site of p53 in MEF cultured cells of syno.
- FIG. 5 is a photograph of Western blotting which was used to examine how phosphorylation of Serl5 enhanced by siRNA treatment of synoviolin was affected by the addition of caffeine.
- FIG. 6 is a photograph of a Western plot showing that expression of p53 and p21 is increased by siRNA treatment of Synoviolin.
- FIG. 7 is a view showing a result of observation of a cell cycle by a flow cytometer.
- FIG. 8 is a photograph showing the result of immunostaining of a Tissue array using an anti-Synobiolin antibody (10 Da).
- FIG. 9 is a photograph showing the result of immunostaining of a Tissue array using an anti-Synoviolin antibody (10 Da).
- FIG. 10 is a photograph showing the localization of p53 in cells into which GFP wild-type p53 has been introduced.
- Figure 11 shows strong expression of GFP wild-type p53 and FLAG wild-type synoviolin, and staining of nuclei with 400-fold diluted primary antibody a-FLAG antibody, 200-fold diluted secondary antibody ⁇ mouse IgG-TRITC or 1M DAPI And observation of the localization of p53 It is.
- Figure 12 shows strong expression of GFP wild-type p53 and FLAG Synoviolin C307S, and staining of nuclei with 400-fold diluted primary antibody a-FLAG antibody, 200-fold diluted secondary antibody, and mouse IgG-TRITC or 1 DAPI. This is a photograph observing the localization of p53.
- FIG. 13 is a photograph showing the in vitro ubiquitination reaction of GST_p53 by MBP-Synoviolin dTM-His.
- FIG. 14 is a graph showing p53 mRNA levels in RA synovial cells by synoviolin RNAi.
- FIG. 15 is a schematic diagram of the prepared p53 binding domain deletion product, and a diagram showing the results of the binding assay.
- Figure 1 6 is a graph showing the results of GST pull-down Atsusi for p53 binding domain deletions and 35 S-p53.
- the present invention by Rukoto p53 by inhibiting expression of Shinobiorin and / or function (meaning P 53 Gansomosomo system gene or p53 protein) is localization and activity in the nucleus, to suppress cancer Features.
- the present invention relates to a method for inhibiting the expression and / or function of synoviolin, wherein p53 is activated by phosphorylase to activate p53, and the expression of p21, a cyclin-dependent kinase inhibitor, is increased. finding that a result, suppresses the expression of p 53 findings and Shinobiori emissions of cancer development or inhibit the growth by migration to S phase is found hinder the G1 phase of the cancer cells through its Interview bi chitin ligase It was completed based on
- p53 When normal cells are exposed to ultraviolet light, etc., intracellular p53 is activated and, as a result, cell proliferation is inhibited. It can stop the growth of vesicles. In other words, when p53 does not function, the growth of cancer cells cannot be stopped and cancer progresses. In fact, p53 is rarely found in cells of normal individuals, but about half of cells from cancer patients have this p53 deletion mutation. Even in the absence of such mutations, some mutations have occurred in the control mechanism of p53 and the tumor suppressor function has been lost. Therefore, it is necessary to make p53 function effectively to suppress the progression of cancer. .
- synoviolin the function of synoviolin was focused on in order to make p53 activation one of the effective methods for cancer treatment. Then, a Synoviolin homo-knockout animal was prepared and analyzed in detail. As a result, a greater number of cells undergoing apoptosis were observed as compared to the wild type. In other words, it was found that inhibiting the function of synoviolin promoted the activation of p53, which is deeply involved in apoptosis, and found that inhibition of the function of synoviolin leads to cancer suppression.
- Synoviolin means that transcription and translation of a gene encoding Synoviolin occurs, or that the transcription and translation of these genes produce Synoviolin protein.
- function of synoviolin means suppressing the activation of p53, and the function of synoviolin includes a function of synoviolin binding to p53 and a function of ubiquitinating p53. Therefore, “inhibiting the expression and / or function of synoviolin” refers to reducing or eliminating the amount, function or activity of a wild-type synoviolin gene or protein as compared to the amount, function or activity thereof. The term “inhibition” includes both inhibition of both function and expression, and inhibition of one or the other.
- Synoviolin promotes the ubiquitination of p53, so it can inhibit the ubiquitination of p53 by inhibiting the binding of synoviolin to p53, and if the inhibition of ubiquitination of p53, It can be said to be activated and eventually lead to suppression of cancer.
- Apoptosis refers to programmed cell death that cells cause themselves, including chromosome aggregation of the nucleus, fragmentation of the nucleus, loss of cell surface microvilli, aggregation of the cytoplasm, activation of caspases, and mitochondrial membrane potential. Characterized by disappearance And Apoptosis is determined to have occurred when a cell has the above characteristics.
- p53 when immunostaining of p53 in a fetal embryo is performed, p53 is strongly expressed in the whole body of a synoviolin homo knockout mouse embryo.
- Fetal fibroblasts (MEFs) isolated from Synoviolin homo-knockout mouse embryos also express more strongly than those isolated from wild-type, and p53 is strongly localized in the nucleus. This nuclear localization is not observed at all in the wild type.
- synoviolin and p53 When synoviolin and p53 are overexpressed, p53 co-localizes with synoviolin in the cytoplasm. This means that p53 can be translocated into the nucleus by inhibiting the expression and / or function of synoviolin.
- Synoviolin homo-knockout mouse embryo MEFs show high radiation or ultraviolet sensitivity. Therefore, in the present invention, after p53 is transferred to the nucleus of the cancer cell by inhibiting the expression and / or function of synoviolin in the cancer cell, irradiation or ultraviolet irradiation of p53 results in Proliferation can be effectively suppressed.
- the radiation irradiating means is not particularly limited. For example, ⁇ -rays can be irradiated with 1 to LOG y.
- ultraviolet rays (wavelength: 100 to 400 nm, preferably 290 to 400 nm) can be irradiated using an appropriate ultraviolet irradiation device (Funakoshi, Dermalei, Keyence, etc.).
- the present invention can suppress cancer efficiently by further contacting a cell containing p53 localized in the nucleus (particularly a cancer cell) with an anticancer agent.
- cancer can also be suppressed by embolizing vessels (for example, blood vessels or lymph vessels) around cancer cells containing p53 localized in the nucleus.
- Anti-cancer agents include alkylating agents, antimetabolites, microtubule inhibitors, platinum complex compounds, and molecularly targeted therapeutics. Specific examples of these anticancer agents include the following, but are not limited thereto.
- Alkylsulfone Busulfan, etc. Nitrosourea type: -Mustin, Mouth mucin, etc.
- Purine derivatives mercaptopurine, azathioprine, etc.
- Pyrimidine derivatives 5-Funoleo mouth peracyl, tegafur, carmofur, etc.
- Bin force Lloyd Vincristine, vinblastine, etc.
- Taxanes paclitaxel, docetaxel, etc.
- Cisplatin Cisplatin, carpoplatin, etc.
- a method for contacting an anticancer drug such as imatinib, rituximab, and gefitinib with a cancer cell is as follows: adding an anticancer drug to a cell or tissue (cancer cell or cancer tissue) containing cells where P53 is localized in the nucleus Or a method of administering an anticancer agent to a cancer-bearing patient or animal.
- the treatment amount of the anticancer agent is not particularly limited, but when added, is 100 ⁇ to 100 ⁇ , preferably 1 ⁇ to 10 ⁇ .
- the dose is 0.1 to: LOO mg / kg / day, preferably 2 to 25 mg / kg / day.
- endoxane is used as an anticancer agent
- the dose is 0.1 to: LOO mg / kg / day, preferably 2 to 25 mg / kg / day.
- Those skilled in the art can appropriately set the dose or the amount of addition of anticancer agents other than endoxane.
- a thrombus is formed in a blood vessel around a cell population or tissue containing cancer cells where p53 is localized in the nucleus.
- an embolus by fat or an embolus by air gas may be formed.
- the present invention is characterized in that p53 is activated by phosphorylating a part of the amino acid residues of p53.
- the amino acid residue targeted for phosphorylation leading to p53 activation is preferably a serine residue in the amino acid sequence of p53, and the 15th serine residue (Serl5) is more preferred.
- Phosphorylation of P53 Serl5 increases p53 expression and enhances transcriptional activity, resulting in increased transcripts.
- Phosphorylation of Serl5 of p53 is closely related to kinases such as ATM (ataxia-telangiectasia mutated) and ATR (ataxia-teiangiectasia related).
- ATM is a causative protein of ataxia telangiectasia, an autosomal recessive genetic disease in humans, and regulates cell growth by sensing DNA damage and phosphorylating the tumor suppressor gene p53. It has a function to troll.
- ATR a member of the ATM family, is induced by a wide range of chemotherapeutic drugs, ultraviolet radiation, or inhibition of protein kinases, and is involved in the activation of p53 that is not involved in ATM. It is.
- synoviolin is used to inhibit ATM and ATR activity by using caffeine in experiments for inhibiting the expression and / or function of synoviolin. It turned out to be regulating sex.
- a protein called p21 is known as a substance whose expression is induced by the phosphorylation of Serl5 of p53.
- p21 is a protein that functions as an inhibitor of cyclin-dependent phosphorylase (CDK) activity and plays a role in regulating the cell cycle by inhibiting CDK activity.
- CDK cyclin-dependent phosphorylase
- the CDK plays a key role in cell cycle suppression and works with its partner, the cyclin protein, to regulate, for example, the smooth transition from cell resting state G1 to DNA replication phase S.
- the expression of p21 a CDK inhibitor
- the present invention enhances p53 activation by inducing synoviolin expression and / or function to induce p21 expression, and suppresses cancer by causing CDK inhibition. It is characterized by that.
- Ubiquitination refers to a post-translational modification reaction of a protein by ubiquitin, a protein degradation marker molecule.
- the physiological significance of this ubiquitination has previously been recognized as a tag modification for delivery to the proteosome-based proteolytic machinery. In subsequent studies, the significance of ubiquitination at the present time is positioned as a reversible protein modification system that controls protein function.
- Ubiquitination is specifically performed by repeating the cascade reaction in which enzymes such as ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3) cooperate to produce a protein serving as a substrate.
- Ubiquitin refers to the process of forming a polyubiquitin chain by linking molecules in a branch. This ubiquitin chain is formed via the ⁇ -amino group of the lysine residue at position 48 in the ubiquitin molecule, and serves as a signal for degradation to the 26S proteasome, and It leads to decomposition of the protein. .
- the present invention is characterized in that p53 is activated by inhibiting the expression and / or function of synoviolin.Such activation of p53 is independent of the phosphorylation mechanism of p53. It focuses on the mechanism of inhibition.
- P53 binding domain of Shinobiorin for example, the amino acid sequence of Shinobiorin, a certain region was deleted, the p53 binding domain deletion and several produced, by performing the GST Burda ⁇ emissions mediation Si for 35 S-p53 You can decide.
- the p53 binding domain deletions of the above Shinobiorin be expressed in E. coli or the like as GST- fusion proteins, proteins with 35 S-p53 protein - confirmed by GST pull-down mediation Si method between proteins bound I do.
- Synoviolin was a 35-amino acid residue at positions 236 to 270 of the amino acid sequence (SEQ ID NO: 2) contained in the Synoviolin protein.
- Synoviolin promotes ubiquitination of p53. Therefore, by inhibiting the function of synoviolin to bind to p53, which is one of the functions of synoviolin, ubiquitination of p53 is inhibited and p53 is activated.
- the region of the Synoviolin protein involved in binding to ⁇ 53 ' is preferably the region from position 236 to position 270 of the amino acid sequence of Synoviolin. Therefore, it is preferable to select mainly the above region as a target region for binding inhibition.
- antagodist small molecule compound, peptide, etc.
- the yeast-to-hybrid method or the ubiquitination activity measurement method. can do.
- an antibody recognizing the 236-270th region of Synoviolin can be reacted with Synoviolin, and the binding between Synoviolin and ⁇ 53 can be inhibited by these methods.
- RNA interference can be used.
- RNAi can be induced by designing and synthesizing siRNA (small-interfering RNA) for the synoviolin gene and introducing it into cells.
- RNAi is a phenomenon in which dsRNA (double-strand RNA) binds specifically and selectively to a target gene, and the target gene is cleaved to efficiently inhibit its expression.
- dsRNA double-strand RNA
- siRNA The design of siRNA can be performed as follows.
- the gene is not particularly limited as long as it is a gene that encodes Synoviolin, and any arbitrary region can be used as a candidate.
- any region of GenBank Accession number AB024690 SEQ ID NO: 1 can be a candidate.
- a sequence starting with AA is selected from the selected region, and the length of the sequence is 19 to 25 bases, preferably 19 to 21 bases.
- the sequence should have a GC content of, for example, 40-60%.
- a DNA containing at least one sequence selected from the following nucleotide sequences among the nucleotide sequences shown in SEQ ID NO: 1 can be used as a target sequence of siRNA. In particular, it targets (i) (SEQ ID NO: 3), (ii) (SEQ ID NO: 4), (vi) (SEQ ID NO: 8), (vii) (SEQ ID NO: 9), (viii) (SEQ ID NO: 10) Is preferred.
- siRNA synthesized in vitro a method of linking siRNA synthesized in vitro to plasmid DNA and introducing this into cells, a method of annealing two RNAs, and the like can be employed.
- shRNA is an RNA molecule having a stem-loop structure because a part of a single strand forms a complementary strand with another area, which is called short hairpin (RNA).
- shRNAs can be designed such that a portion forms a stem-loop structure. For example, if the sequence of a certain region is sequence A and the complementary strand to sequence A is sequence B, these sequences are present in one RNA strand in the order of sequence A, spacer, and sequence B. So that the total length is 45 to 60 bases.
- Sequence A is a sequence of a partial region of a target Synoviolin gene (SEQ ID NO: 1), and the target region is not particularly limited, and any region can be a candidate.
- the length of sequence A is 19-25 bases, preferably 19-21 bases.
- the shRNA and siRNA produced in the present invention are substances that inhibit the expression and / or function of synoviolin, and can be used as a pharmaceutical composition for activating p53 (particularly a gene therapy agent for cancer).
- the site of application is not particularly limited, and brain tumor, tongue cancer, pharynx cancer, lung cancer, breast cancer, esophagus cancer, stomach cancer, kidney cancer, biliary tract cancer, Gallbladder cancer, duodenal cancer, colon cancer, liver cancer, ovarian cancer, ovarian cancer, prostate Adenocarcinoma, renal cancer, bladder cancer, rhabdomyosarcoma, fibrosarcoma, osteosarcoma, chondrosarcoma, skin cancer, various leukemias (eg acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphatic Applicable for leukemia, adult T-cell leukemia, malignant lymphoma), etc.
- the above-mentioned cancer may be a primary tumor, metastasized, or co-occurring with another disease.
- the pharmaceutical composition of the present invention When the pharmaceutical composition of the present invention is used as a gene therapy agent, there are mentioned a method of directly administering the pharmaceutical composition of the present invention by injection, and a method of administering a vector into which a nucleic acid has been incorporated.
- the vector include an adenovirus vector, an adeno-associated virus vector, a heterozygous innores vector, a vaccinia virus vector, a retrovirus vector, a lentivirus vector, and the like. It can be administered efficiently.
- the pharmaceutical composition of the present invention into phospholipid vesicles such as ribosomes and administer the vesicles.
- the endoplasmic reticulum holding the siRNA or shRNA is introduced into predetermined cells by the ribofusion method. Then, the obtained cells are systemically administered, for example, into a vein, an artery or the like. It can also be administered locally to the brain and the like.
- the dosage of the pharmaceutical composition of the present invention age, sex, symptoms, administration route, frequency of administration, dosage form by different, for example, the dosage in the case of adenovirus 10 6 ⁇ 10i 3 or so per day And is administered at 1 to 8 week intervals.
- RNA introduction kit for example, AdenoExpress: Clontech
- P53 in Synoviolin homo knockout mouse (syno-/-) fetal fibroblasts (MEFs) was detected by Western blotting, and the cells were confirmed by immunohistochemical staining. That is, in the immunostaining method, MEFs were fixed on a slide glass according to a conventional method, and immunostaining was performed using an anti-p53 antibody (mouse monoclonal antibody BD: Becton, Dickinson). 0.3 ° // for specimens blocked for 30 minutes with 3% bovine serum albumin (BSA). An anti-p53 antibody (BD: 10 pg / ml) diluted with BSA was immunoreacted at room temperature for 60 minutes.
- an anti-p53 antibody (BD: 10 pg / ml) diluted with BSA was immunoreacted at room temperature for 60 minutes.
- the specimen was washed with PBS, and immunoreacted with a TRITC-labeled anti-mouse IgG antibody (Dako) as a secondary antibody.
- the antigen immunoreactive with the anti-p53 antibody was confirmed with a fluorescence microscope.
- immunostaining of syno fetal embryos was performed using Vectastin ABC Kit (VECTOR) after fixing the tissue on a slide glass according to a conventional method.
- the specimen blocked with the blocking reagent for 30 minutes was immunoreacted with the anti-p53 antibody FL393 diluted to 5 pg / ml at room temperature for 60 minutes.
- the specimen was washed with PBS, and immunoreacted with an HRP-labeled anti-Egret IgG antibody as a secondary antibody.
- the antigen immunoreactive with the anti-p53 antibody was confirmed by the color development of 3,3'-diaminobenzidine tetrahydrochloride based on HRP activity. Methyl green staining was performed as counterstain.
- p53 in syno-/-MEF cultured cells was detected by Western blotting.
- cell lysate 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP40, 1 mM PMSF, 0.1% sodium dodecyl sulfate (SDS), 2 g / ml Leupeptin, 2 g / ml Aprotinin, 2pg / ml Pepstatin
- SDS sodium dodecyl sulfate
- 2 g / ml Leupeptin 2 g / ml Aprotinin
- Pepstatin 0.1% sodium dodecyl sulfate
- SDS-PAGE SDS polyacrylamide electrophoresis
- cell-derived proteins were transferred to nitrocellulose (NC) membranes by electoral port plotting.
- the anti-p53 antibody c-terminal aa; 195.393 or FL393 was diluted with TBS containing 5% skim milk. The reaction was carried out at room temperature for 1 hour. After the reaction, the NC membrane was washed with 0.1% Tween20 / TBS, immunoreacted with horse radish peroxidase (HRP) -labeled anti-Peacock IgG antibody as a secondary antibody at room temperature for 1 hour, washed with 0.1% Tween20 / TBS, and washed with HRP activity. Was detected to detect the target antigen. For detection of HRP activity, an ECL kit (Amersham) was used (Clinical Chemistry. 25, pl531, 1979).
- the phosphorylation site of p53 was identified by Western blotting using an anti-p53 antibody.
- anti-phosphorylated p53 monoclonal antibodies that recognize phosphorylation of different serine residues of p53 (SEQ ID NO: 17) (Phospho-p53 (serl5), Phospho-p53 (ser20), Phospho-p53 (ser37 ) And Phospho-p53 (ser46); Becton, Dickinson), the proteins of MEF cells were separated by SDS'PAGE, and Western blotting was performed.
- the operation of the Western blotting method is as described in Example 3 except that an anti-phosphorylated p53 monoclonal antibody is used as a primary antibody and an anti-mouse IgG hidge-HHP is used as a labeled antibody.
- RKO human colon cancer-derived cell line
- p53 wild-type p53 as a cell line
- a 60 mm plate at l.OxlO 5 cells / 12 mL plate
- ATM ataxia-telangiectasia mutated
- ATR ATM and Rad3 related
- RKO cells were treated with siRNA against Synoviolin, and changes in the expression of p21, a transcript of p53, were examined by Western plotting.
- the RA synovial cells were seeded at 9.0Xl0 4 cells 10 cm dish, after Shinobiorin siRNA (final concentration 25 nM) were transfected Hue Tato, was observed cell cycle by Furosai Tome one coater. As a result, with the siRNA at 25 nM (No. 589), a delay in the cell cycle in the G0 / G1 phase was observed (FIG. 7).
- h589 was used as siRNA.
- h589 means a double-stranded RNA obtained by annealing the following sense strand and antisense strand.
- Sense strand h589 GGU GUU CUU UGG GCA ACU G TT (SEQ ID NO: 18)
- Antisense strand h589 CAG UUG CCC AAA GAA CAC C TT (SEQ ID NO: 19)
- Tissue array (CHEMICON individual soil: 10 common human cancer tissue with normal human tissue) was immunostained using an anti-synoviolin antibody (10 Da).
- the antibody concentration used for immunostaining was 8 IX g / ml and the kit used was Simplex MAX (M).
- synoviolin in normal tissues was found in colon, kidney, lung, ovary, testis, skin and mammary gland, but not in nerve and lymph nodes.
- the expression of synoviolin was confirmed in each tumor tissue, and in particular, the tissues judged to have significantly increased expression were nerve and lymph nodes ( Figures 8 and 9).
- Each plasmid is as follows.
- GFP-p53 expression of green fluorescence protein and funky protein of wild-type 53
- FLAG-synoviolin Expression of wild-type synoviolin with FLAG tag
- FLAG-synoviolin C307S (without ubiquitin (Ub) -forming activity): Inactivated synoviolin expression with FLAG tag 24 hours after transfection with fuGENEG (Roche), fixed with 10% formalin, 400-fold diluted primary antibody a The nucleus was stained with -FLAG antibody, 200-fold diluted secondary antibody ⁇ -mouse IgG-TRITC, and 1 M DAPI, and its localization was observed.
- wild-type p53 was localized in the nucleus when strongly expressed (FIG. 10).
- wild-type Synoviolin was overexpressed, it was localized in the cytoplasm (particularly around the nucleus).
- wild-type p53 and wild-type synoviolin were strongly expressed, it was observed that p53 originally localized in the nucleus was distributed in fine dots around the nucleus and co-localized with synoviolin (Fig. 11). ).
- wild-type p53 and Synoviolin C307S mutant were strongly expressed, it was observed that p53 formed a large dot in the cytoplasm and co-localized with Synoviolin (FIG. 12).
- Example 10 Examination of in vitro ubiquitination of GST-p53 by MBP-Synoviolin dam-His Changes in intracellular p53 protein level were observed due to increase and decrease in intracellular synoviolin, suggesting that synoviolin regulates p53. Therefore, in order to investigate whether synoviolin directly ubiquitinates (Ub) p53, we examined the in vitro ubilation reaction using GST-p53 and MBP-Synoviolin dTM-His.
- GST-p53 A fraction obtained by expressing p53 with GST fused to the N-terminal side in Escherichia coli and generating it.
- MBP-Synoviolin dTM-His A fraction obtained by expressing Synoviolin with MBP fused to the N-terminus and His tag fused to the C-terminus in E. coli and purifying it.
- E. coli, which holds the pGEX / P 53 a (BL21) were cultured in LB medium 500 ml, after induction with IPTG (1 mM, 30 ° C , 6h), with a buffer containing 0.5% NP-40 from the culture medium An E. coli extract was prepared.
- GST-p53 was purified from E. coli extract using GSH-Sepharose resin in the presence of 0.1% NP-40. Using the sample after the dialysis, the reaction was performed in combination with MBP-Synoviolin dTM-His and other compositions used for in vitro Ub formation reaction (ATP, PK-His-HA_Ub, yeast El, His-UbcH5c). ( Figure 13). After the reaction, the proteins were separated by 7.5% SDS-PAGE, transferred to a PVDF membrane, and the p53 protein on the membrane was detected with an anti-p53 antibody (FL393 or DO-1). The same reaction and detection were performed by changing the amount of GST-p53 added.
- Example 11 Examination of synoviolin and p53 mRNA levels under RNAi
- the effects of synoviolin on cell cycle, apoptosis, etc. were examined by examining changes in mRNA levels of synoviolin and related genes over time under the conditions of synoviolin RNAi.
- RA synovial cells were seeded in a 30000 cells / 10 cm dish, transfected with 25 nM siRNA (No. 589) according to a standard method, and the cells were collected over time during 4 days of cell culture to obtain mRNA.
- Reverse transcription PCR was performed using l ⁇ g mRNA as a template and random primers to obtain cDNA.
- the obtained cDNA was quantified using ABI TaqMan Gene expression assay (GEX). MRNA amount was calculated using 18S rRNA as a control gene.
- the GEX reagent target accession No. was 1 ml for Synoviolin and 1 ml for TP53 Hs00153340_ml.
- a synoviolin p53-binding domain deletion mutant was prepared and 35 S- GST pull-down assay was performed on p53 as follows (Fig. 16).
- Competent cells BL-21 strain
- plasmid encoding L of each GST protein.
- the names of each GST protein and plasmid were as follows.
- 80 zL of 50% -slurry Glutathione Sepharose beads were added, and the mixture was rotated at 4 ° C for 2 hr to bind the GST protein to the beads.
- TNT Reticulocyte Lysate (-80 ° C) 25 ⁇ L
- TNT polymerase (Culture room-20 ° C) 1 / L
- IvTL In vitro Translation Product
- the beads were washed four times with 1 ml of Pull-down Buffer V. At this time, about 100 ⁇ L of the supernatant was always left, so that beads were not absorbed. Centrifugation was performed at 2500 rpm, 1 min, and 4 ° C. After sucking the supernatant, 40 ⁇ of 1X SDS Sample Buffer was added to prepare a Pulldown sample. On put 10% and Pull-down samples were heated at 100 ° C for 5 minutes and stored at -20 ° C. The next day, the samples were warmed to 10 min in a 37 ° C constant temperature bath and applied to a 10% gel.
- a substance that promotes the activity of a p53 tumor suppressor gene is provided. Since this substance can activate p53 and transfer p53 to the nucleus, it is useful as a pharmaceutical composition for treating cancer.
- cancer can be treated by inhibiting the expression and / or function of synoviolin. Sequence listing free text
- SEQ ID NO: 17 Synthetic oligonucleotide (DNA / RNA mixture)
- SEQ ID NO: 18 synthetic oligonucleotide (DNA / RNA mixture)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04808150A EP1709973A1 (en) | 2003-12-24 | 2004-12-24 | Method of suppressing cancer |
JP2005516545A JPWO2005061001A1 (ja) | 2003-12-24 | 2004-12-24 | 癌の抑制方法 |
AU2004305386A AU2004305386A1 (en) | 2003-12-24 | 2004-12-24 | Method of suppressing cancer |
US10/584,289 US20080039409A1 (en) | 2003-12-24 | 2004-12-24 | Method of Suppressing Cancer |
CA002551543A CA2551543A1 (en) | 2003-12-24 | 2004-12-24 | Method of suppressing cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-428300 | 2003-12-24 | ||
JP2003428300 | 2003-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005061001A1 true WO2005061001A1 (ja) | 2005-07-07 |
Family
ID=34708926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/019800 WO2005061001A1 (ja) | 2003-12-24 | 2004-12-24 | 癌の抑制方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080039409A1 (ja) |
EP (1) | EP1709973A1 (ja) |
JP (1) | JPWO2005061001A1 (ja) |
KR (1) | KR100809890B1 (ja) |
CN (1) | CN1909927A (ja) |
AU (1) | AU2004305386A1 (ja) |
CA (1) | CA2551543A1 (ja) |
WO (1) | WO2005061001A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006137514A1 (ja) * | 2005-06-23 | 2006-12-28 | Locomogene, Inc. | シノビオリンの発現もしくは機能阻害物質を有効成分とする癌治療剤、および癌治療剤のスクリーニング方法 |
EP2940132A4 (en) * | 2012-12-26 | 2016-08-17 | Nakajima Toshihiro | SCREENING METHOD FOR A CONNECTION WITH EFFECT TO PREVENT OR TREAT ADIPOSITAS |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100895256B1 (ko) * | 2008-04-30 | 2009-04-29 | 재단법인서울대학교산학협력재단 | Atm/atr을 이용한 세포사멸 조절제 스크리닝 방법 |
BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
US8987274B2 (en) | 2011-10-28 | 2015-03-24 | Merck Sharp & Dohme Corp | Macrocycles that increase p53 activity and the uses thereof |
MX2015008196A (es) | 2012-12-20 | 2015-09-16 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. |
CN104894164A (zh) * | 2015-05-20 | 2015-09-09 | 山西大学 | 一种基于EGFP的GADD45β RNA干扰报告载体构建及应用 |
CN117700518A (zh) * | 2023-02-20 | 2024-03-15 | 浙江大学 | 具有更强液-液相分离能力及活性的p53变体及其用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10503361A (ja) * | 1993-10-29 | 1998-03-31 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 組換えp53アデノウイルス方法と組成物 |
JPH10512559A (ja) * | 1995-01-17 | 1998-12-02 | ローヌ−プーラン・ロレ・エス・アー | 過増殖症の併用療法 |
JP2001502553A (ja) * | 1996-10-29 | 2001-02-27 | ローヌ―プーラン・ロレ・エス・アー | 抗p53一本鎖抗体フラグメント及びその使用 |
JP2001511815A (ja) * | 1997-02-18 | 2001-08-14 | カンジ,インコーポレイテッド | 新生物の処置における腫瘍抑制遺伝子治療および化学治療の組合せ |
WO2002052007A1 (fr) * | 2000-12-22 | 2002-07-04 | Locomogene, Inc. | Proteine de cellule de membrane synoviale |
JP2002531396A (ja) * | 1998-12-02 | 2002-09-24 | ファイザー・プロダクツ・インク | p53ファミリーのタンパク質の配座安定性を回復するための方法及び組成物 |
WO2003008573A2 (en) * | 2001-07-17 | 2003-01-30 | Anne Josephine Milner | Silencing of gene expression by sirna |
-
2004
- 2004-12-24 CN CNA2004800388346A patent/CN1909927A/zh active Pending
- 2004-12-24 EP EP04808150A patent/EP1709973A1/en not_active Withdrawn
- 2004-12-24 AU AU2004305386A patent/AU2004305386A1/en not_active Abandoned
- 2004-12-24 WO PCT/JP2004/019800 patent/WO2005061001A1/ja not_active Application Discontinuation
- 2004-12-24 KR KR1020067012511A patent/KR100809890B1/ko not_active IP Right Cessation
- 2004-12-24 JP JP2005516545A patent/JPWO2005061001A1/ja active Pending
- 2004-12-24 CA CA002551543A patent/CA2551543A1/en not_active Abandoned
- 2004-12-24 US US10/584,289 patent/US20080039409A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10503361A (ja) * | 1993-10-29 | 1998-03-31 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 組換えp53アデノウイルス方法と組成物 |
JPH10512559A (ja) * | 1995-01-17 | 1998-12-02 | ローヌ−プーラン・ロレ・エス・アー | 過増殖症の併用療法 |
JP2001502553A (ja) * | 1996-10-29 | 2001-02-27 | ローヌ―プーラン・ロレ・エス・アー | 抗p53一本鎖抗体フラグメント及びその使用 |
JP2001511815A (ja) * | 1997-02-18 | 2001-08-14 | カンジ,インコーポレイテッド | 新生物の処置における腫瘍抑制遺伝子治療および化学治療の組合せ |
JP2002531396A (ja) * | 1998-12-02 | 2002-09-24 | ファイザー・プロダクツ・インク | p53ファミリーのタンパク質の配座安定性を回復するための方法及び組成物 |
WO2002052007A1 (fr) * | 2000-12-22 | 2002-07-04 | Locomogene, Inc. | Proteine de cellule de membrane synoviale |
WO2003008573A2 (en) * | 2001-07-17 | 2003-01-30 | Anne Josephine Milner | Silencing of gene expression by sirna |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006137514A1 (ja) * | 2005-06-23 | 2006-12-28 | Locomogene, Inc. | シノビオリンの発現もしくは機能阻害物質を有効成分とする癌治療剤、および癌治療剤のスクリーニング方法 |
EP2940132A4 (en) * | 2012-12-26 | 2016-08-17 | Nakajima Toshihiro | SCREENING METHOD FOR A CONNECTION WITH EFFECT TO PREVENT OR TREAT ADIPOSITAS |
Also Published As
Publication number | Publication date |
---|---|
US20080039409A1 (en) | 2008-02-14 |
JPWO2005061001A1 (ja) | 2007-07-12 |
CN1909927A (zh) | 2007-02-07 |
EP1709973A1 (en) | 2006-10-11 |
KR100809890B1 (ko) | 2008-03-06 |
CA2551543A1 (en) | 2005-07-07 |
KR20070003798A (ko) | 2007-01-05 |
AU2004305386A1 (en) | 2005-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | TRIM21 overexpression promotes tumor progression by regulating cell proliferation, cell migration and cell senescence in human glioma | |
Chen et al. | Activation of JNK and p38 MAPK mediated by ZDHHC17 drives glioblastoma multiforme development and malignant progression | |
Qiu et al. | Nrdp1‐mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis | |
CA2841203C (en) | Apoptosis-inducing agent | |
Al‐Matouq et al. | CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death | |
Wang et al. | DDR2 induces gastric cancer cell activities via activating mTORC2 signaling and is associated with clinicopathological characteristics of gastric cancer | |
Zheng et al. | Membrane‐tethered Notch1 exhibits oncogenic property via activation of EGFR–PI3K–AKT pathway in oral squamous cell carcinoma | |
Weiswald et al. | Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2 | |
WO2005061001A1 (ja) | 癌の抑制方法 | |
WO2006137514A1 (ja) | シノビオリンの発現もしくは機能阻害物質を有効成分とする癌治療剤、および癌治療剤のスクリーニング方法 | |
KR102282304B1 (ko) | Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물 | |
Heminger et al. | Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53 | |
Park et al. | LNX1 contributes to tumor growth by down‐regulating p53 stability | |
US8809295B2 (en) | Composition containing inhibitors of the expression or activity of SH3RF2 for preventing or treating cancer | |
Dong-Xiang et al. | Cyclin-dependent kinase like 3 promotes triple-negative breast cancer progression via inhibiting the p53 signaling pathway. | |
US10768179B2 (en) | Method for predicting responsiveness to cancer treatment using p300-inhibiting compound | |
KR101776864B1 (ko) | Npffr2 억제제를 유효성분으로 포함하는 암 전이 억제 및 암 치료용 조성물 | |
Hoj | The Characterization of Tyrosine Kinase-Dependent Signaling Networks Required for Lung Cancer Brain Metastasis | |
Xu et al. | Cellular communication network 1 promotes CASP2 mRNA expression but suppresses its protein translation in esophageal adenocarcinoma | |
Zhang et al. | Endothelial cell-derived SSAO can increase MLC20 phosphorylation in VSMCs | |
Goldbraikh et al. | USP1 deubiquitinates protein kinase Akt to inhibit PI3K-Akt-FoxO signaling | |
KR20220044040A (ko) | Lrp5 발현 또는 활성 억제제를 포함하는 허혈성 심장질환의 예방 또는 치료용 약학적 조성물 | |
WO2005061007A1 (ja) | 癌の抑制方法 | |
Leech | Mechanisms of Crosstalk between JAM-A and HER2 driving Breast Cancer | |
Deshpande | The effects of lowering VHL protein in rat pheochromocytoma PC12 cell lines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480038834.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516545 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067012511 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2551543 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004305386 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004808150 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004305386 Country of ref document: AU Date of ref document: 20041224 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004305386 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004808150 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067012511 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10584289 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10584289 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004808150 Country of ref document: EP |